




EY Entrepreneur
of the year-2013



FROST & SULLIVAN
Best Practices-2013



Business today/YES bank
Excellence Awards-2013

Eris
Eris Lifesciences Ltd.

November 18th 2017

Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

Scrip code: 540596

The National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex
Bandra (E) Mumbai - 400 051

Scrip code: ERIS

Dear Sirs,

Sub: Acquisition of India brand business of Strides Shasun Limited

We wish to inform you that the Company has today entered into definitive agreements with Strides Shasun Limited for the acquisition of 'India brand business' for a cash consideration of INR 500 Crores.

With this acquisition, Eris's fourth—and the largest—in the last 18 months, the Company will be among the top ten companies in the Central Nervous System (CNS) segment. Eris is already among the top 20 companies in the cardiology segment and ranks among the top ten in the diabetology segment.

Since inception in 2007, Eris has focused on the "chronic segments" of cardiology and diabetology. Eris had forayed into the CNS segment only recently. This acquisition cements Eris's position in the top three chronic segments.

Post-acquisition the company will break into the league of top 25 companies having a market share of more than 1% in the Indian Pharmaceutical Market.

We attach herewith a press release issued by the Company on the occasion along with Disclosure under Regulation 30 of SEBI (LODR).

Thanks & Regards,
For ERIS LIFESCIENCES LIMITED


Milind Talegaonkar
Company Secretary

Registered & Corporate Office:


8th Floor, Commerce House - IV, Prahlad Nagar, Ahmedabad - 380 015, Gujarat, India

Phone: +91 - 79 - 30451111 / 30179402 - 03 • Fax: +91 - 79 - 30179404 / 30451001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in


CIN: L24232GJ2007PLC049867



EY Entrepreneur
of the year-2013



FROST & SULLIVAN
Best Practices-2013



Business today/YES bank
Excellence Awards-2013

Eris
Eris Lifesciences Ltd.

Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sr. No	Particulars	
1.	Name of the Target entity, details in brief such as size, turnover etc.	The branded generics business in India of Strides Shasun Limited and Strides Healthcare Private Limited. The business had a turnover of INR 181crores in FY 2016-17
2.	Whether the acquisition of the Target entity falls within the related party Transaction and whether the promoter/ promoter group/group companies have any interest in the entity being acquired	No
3.	Industry to which Target entity being acquired belongs	Pharmaceuticals - Branded Generics
4.	Objects and effects of acquisition	Eris will expand its coverage of the Indian Pharma market (IPM) by about 40% and improve its rank by 4 places to No. 25 in the IMS. The acquisition strengthens Eris' position as a chronic focussed specialty player with emergence of the Central Nervous System (CNS) therapy as the third largest therapy for Eris. The CNS therapy is a difficult to enter primary therapy with characteristics of strong sales stickiness.
5.	Brief details of any governmental or regulatory approvals required for the acquisition	None anticipated
6.	Indicative time period for completion	November 30 th 2017
7.	Nature of consideration	Cash
8.	Percentage of shareholding/ control acquired and/ or number of shares acquired	Strides Shasun Limited: The branded generics business in India Strides Healthcare Private Limited: 100% of the equity shares
9.	Cost of acquisition or the price at which the shares are acquired	INR 500crores
10.		
a.	Products/line of business acquired	Branded generics business in India

Registered & Corporate Office:

8th Floor, Commerce House - IV, Prahlad Nagar, Ahmedabad - 380 015, Gujarat, India

Phone: +91 - 79 - 30451111 / 30179402 - 03 • Fax: +91 - 79 - 30179404 / 30451001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in

CIN: L24232GJ2007PLC049867

b.	Date of incorporation	June 17- 2013	
c.	History of last 3 years turnover* (INR Cr) <i>*for the business being acquired</i>	FY 2016-17	181
		FY 2015-16	108
		FY 2014-15	112
d.	Country in which the acquired entity has presence	India	
e.	Any other significant information		

For ERIS LIFESCIENCES LIMITED



Milind Talegaonkar

Company Secretary